ERBB2 and breast cancer: Muraro et al. [39] performed immunophenotyping on PB from HER2+ BC patients who received neoadjuvant chemotherapy combined with trastuzumab and did not observe the increase in the percentage of T lymphocytes after therapy that we saw in our cohort.